R&D

Eli Lilly making renewed push in biotech field, where it once pioneered

August 16, 2014
J.K. Wall
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
More

Roche drug trial backs Lilly on Alzheimer’s findings

July 28, 2014
J.K. Wall
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer's.
More

Merck's exit pushes Endocyte shares lower

June 18, 2014
 IBJ Staff
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.
More

Lilly says its once-daily insulin tops competitor's drug

May 12, 2014
Bloomberg News
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
More

Blockbuster deal: Eli Lilly paying $5.4B for Novartis Animal Health

April 22, 2014
 IBJ Staff
Eli Lilly and Co. has agreed to pay $5.4 billion for Novartis Animal Health in the second-largest deal in the company's history. The acquisition is part of a blockbuster three-way drug deal.
More

Discovery may be key to Alzheimer's treatment

March 20, 2014
Bloomberg News
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
More

Analysts: Endocyte likely to receive green light on first drug this month

March 3, 2014
J.K. Wall
The European Committee for Medicinal Products for Human Use is scheduled to meet March 17-20, and analysts expect the agency to vote during that meeting to approve vintafolide, Endocyte’s first drug, which treats ovarian cancer.
More

Lilly diabetes drug matches competitors' effectiveness

February 25, 2014
 IBJ Staff and Bloomberg News
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
More

Lilly foe still testing Alzheimer's theory where others failed

December 12, 2013
Bloomberg News
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
More

Lilly depression drug fails to meet goals in studies

December 5, 2013
Bloomberg News
Edivoxetine, a derivative of Lilly's Strattera drug for attention deficit disorder, was in the final of three stages of testing usually required for marketing approval by U.S. regulators.
More

Lilly pledges up to $1.8B to Pfizer for access to potential blockbuster

November 11, 2013
J.K. Wall
Eli Lilly and Co. and Pfizer Inc., which are both suffering through some of the largest patent cliffs in the industry, will split any future costs and profits of an osteoarthritis drug that has stalled in clinical testing.
More

Investors brace for lean years from LillyRestricted Content

October 12, 2013
J.K. Wall

In a new round of predictions this month, Wall Street analysts indicated they expect Eli Lilly and Co.’s revenue to fall next year and to remain below 2013 levels until 2020.

More

Financial pressures stretching Lilly

October 7, 2013
J.K. Wall
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
More

Lilly shares dip after cancer treatment misses goal

September 26, 2013
Associated Press
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
More

Lilly bets quality over quantity will pay off in diabetes battle

September 24, 2013
Bloomberg News
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
More

Lilly's new strategy built around head-to-head drug trialsRestricted Content

August 10, 2013
J.K. Wall
Lilly has set up not one, not two, but five head-to-head trials of its experimental drug dulaglutide against other leading diabetes therapies. So far, dulaglutide’s record is four wins, no losses.
More

Delta Faucet builds innovation machine in CarmelRestricted Content

August 3, 2013
Dan Human
One of Indiana’s most innovative companies in the past decade doesn’t make surgical instruments or drugs or engines. It makes water faucets and toilets. Delta Faucet Co. has secured 589 patents in the past 20 years.
More

Lilly wins patent lawsuit on J&J Alzheimer’s research

June 25, 2013
Bloomberg News
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
More

Lilly’s experimental diabetes drug helps patients lose weight

June 24, 2013
Bloomberg News
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
More

Lilly to take over development of diabetes drug

June 17, 2013
Associated Press
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
More

Lilly stops development on cancer drug after failed study

May 10, 2013
Bloomberg News
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
More

IU medical school's push to launch startups bears fruitRestricted Content

April 13, 2013
J.K. Wall
The Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity the school has never seen before.
More

J&J wins OK for first in new class of diabetes drugs

March 31, 2013
Bloomberg News
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
More

Lilly, Boehringer submit diabetes drug to FDA

March 25, 2013
Associated Press
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
More

Court may decide if drugmakers can pay to delay generics

March 25, 2013
Associated Press
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
More
Page  1 2 3 4 5 6 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Hello Dear Are you tired of Seeking Loans and Mortgages,have you Been Turned down constantly By your banks and Other Financial Institutions or Micro Finance scheme. This is let you know with 100% guarantee that we Offer loans ranging from $1,000 Minimum to $1,000,000.00 Maximum at 3% interest rate per Month. We give out LOANS for developing business. a competitive edge/business expansion. email address: michealscottloan124@gmail.com We offer the following kinds of loans and many more; * Personal Loans ( Unsecured Loan) * Business Loans ( Unsecured Loan) * Consolidation Loan * Combination Loan * Home Improvement * Xmas Loans for contact to seek for loan email this email address: michealscottloan124@gmail.com Thanks

  2. My name is Mr Henry Josh and i live in the USA California and life is worth living right now for me and my family and all this is because of one man sent by GOD to help me and my family, i once had a life filled with sorrow because my first SON needed a kidney transplant and all our savings were going towards his medications and this normally leaves us with no money to pay our bills or even put enough food on our table and our rent was due and no funds to pay these bills and life felt so unfair to me and every night my wife will cry herself to sleep every night until one day, i was browsing through yahoo answers and i saw a striking advert of a man that gives out personal loans and that the offer is opened to all and i have heard so many things about internet scams but at this point of my life, i was very desperate and ready to take any risk and at the end of the day, i applied for this loan and from one step to another, i got my loan within 12 hours through bank transfer and you know, it was all like a dream and i called Mr Daniel Jones A Man who is the GOD sent lender i found and said, i have received my loan and he smiled stating that to GOD be the glory and i was so shocked as i have never ever seen anyone with such a GOD fearing and kind heart and today, i am the happiest man on earth because by GOD’S grace, my SON kidney transplant was successful and today he is healthy, i and my family are living very comfortable and happy and if you are in my former situation or in serious and legitimate need of a loan, you can reach this GOD sent lender via fidelityloanfirm@outlook.com

  3. Greetings to everyone reading this comment!!! I am Greg William by name. I am out here to recommend the effort of Mark Oscar,I was in need of a consolidation loan amount of 50,000 and as soon as I got in contact with Mark Oscar Loan Firm on Wednesday last week and on Friday last week as well I receive an alert from my bank(Royal Bank of Scotland Group) that the fund was transferred,I want everybody on this site to contact Mark Oscar now via email on how to get a loan because I got my loan from them and I am very happy,so contact them now. Oscarloanfinance@hotmail.com Thanks!!!!!!

  4. Elected officials, like Mourdock, get vested in 8 years. It takes 10 years for all other public employees, most of whom make a lot less money. So much for the promise to finish out his term.

  5. Great state treasurer and a good man!! Just curious if the folks who didn't quite understand his quote would like to tell my daughter-in-law that God didn't intend her! Mourdock's comment was correct but twisted and the article didn't mention that his opponent and the press let the impression stand that Mourdock meant that the rape was intended. Stupid people!!

ADVERTISEMENT